Research from AIA Research Group shows that Increased N-glycosylation of Asn88 in serum pancreatic ribonuclease 1 is a novel diagnostic marker for pancreatic cancer.

The study shows that N-glycosylation at Asn⁸⁸ in serum RNase1 was significantly increased in patients with PaCa. This finding was established using an immunoassay that was developed to determine the level of total RNase1 compared with that of RNase1 that was not N-glycosylated on Asn⁸⁸ (Asn⁸⁸-free). The increase levels of RNase1 with N-glycosylated Asn⁸⁸ in the sera of patients suspected of having PaCa thus shows promise as a novel diagnostic marker for screening and detection of PaCa. The immunoassay and Western blot-base analysis were developed for detecting this change in N-glycosylation of RNase1 using RrhRN0723 mAb and RN3F34 mAb, respectively. Both antibodies directed against human RNase1 recognize the peptide region surrounding the Asn⁸⁸ N-glycosylation site containing unglycosylated Asn⁸⁸, but not when its Asn⁸⁸ is N-glycosylated. The EIA analysis using RrhRN0723 which allows the high-throughput and quantitative detection of the levels of Asn⁸⁸-free RNase1 is suitable for clinical purpose. In contrast, the Western blot analysis using RN3F34 which allows the qualitative detection of the changes in N-glycosylation at Asn⁸⁸ is good for research tool rather than clinical purpose.

Reference:

AIA Research Group , Increased N-glycosylation of Asn88 in serum pancreatic ribonuclease 1 is a novel diagnostic marker for pancreatic cancer, Scientific Reports 4,Article number:6715, doi:10.1038/srep06715